Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blockade in chronic heart failure: does it work in everyone?

Georges Chahoud1, Jacob Joseph

  • 1Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock 72205, USA.

Current Opinion in Cardiology
|September 10, 2003
PubMed
Summary

Beta-blockers significantly reduce mortality and hospitalizations in chronic heart failure patients. Recent evidence confirms their benefit across diverse populations and highlights cost-effectiveness, supporting widespread use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A large-scale multi-ancestry mitochondrial variant association analysis for cardiometabolic traits.

Nature communications·2026
Same author

X-Chromosome-Wide Association Study Identifies Novel Genetic Signals for Heart Failure and Subtypes.

medRxiv : the preprint server for health sciences·2026
Same author

Independent Genetic Effects of Glucagon-like Peptide-1 Receptor Locus on Body Mass Index and Type 2 Diabetes.

medRxiv : the preprint server for health sciences·2026
Same author

Increasing value in the Veterans Affairs Healthcare System (VA) with precision health: a continuing landmark collaboration with the Department of Energy.

Journal of the American Medical Informatics Association : JAMIA·2026
Same author

Management of Arrhythmias in Older Adult Patients ≥75 Years Old Compared to Younger Patients <75 Years Old: Is Contemporary Practice Reflective of Evidence?

Cardiology in review·2026
Same author

Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis.

JACC. CardioOncology·2026

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Chronic heart failure (CHF) presents a significant global health burden with high morbidity and mortality.
  • Despite therapeutic advancements, CHF management remains challenging.

Purpose of the Study:

  • To evaluate the efficacy and applicability of beta-adrenergic blockade in managing chronic heart failure.
  • To synthesize recent evidence on beta-blocker benefits across various patient demographics and cost-effectiveness.

Main Methods:

  • Review of recent clinical trials, meta-analyses, and sub-analyses concerning beta-blocker therapy in heart failure.
  • Analysis of data on patient subgroups including severe heart failure, women, elderly, and African Americans.
  • Assessment of cost-effectiveness data for beta-blockade in CHF.

Related Experiment Videos

Main Results:

  • Beta-adrenergic blockade suppresses sympathetic activity, mitigating adverse ventricular remodeling.
  • Evidence supports beta-blocker benefits in severe heart failure, women, the elderly, and African Americans.
  • Beta-blockade has demonstrated cost-effectiveness in managing chronic heart failure.

Conclusions:

  • Beta-blockade is a cornerstone therapy for chronic heart failure, reducing mortality and hospitalizations.
  • The benefits of beta-blockers are now established across a broad spectrum of heart failure patients.
  • Current evidence strongly supports the use of beta-blockade for the majority of patients with chronic heart failure.